Semaglutide outperformed 7 diabetes medications in reducing risk of Alzheimer's disease, according to a study of over 1 ...

Topline results were announced from a cardiovascular outcomes study evaluating oral semaglutide in patients with type 2 diabetes.

Sanofi and CD&R entered into exclusive negotiations for the potential sale and purchase of a 50% controlling stake in Opella.

Wegovy and similar weight-loss medications are becoming widely prescribed for teenagers with obesity, but little is known ...

A new study found a link between NovoNordisk’s blockbuster drug Ozempic and a reduced risk of Alzheimer’s disease. 23andMe, ...

Semaglutide medications — such as Ozempic, the popular diabetes medication — have been linked to a reduced risk of ...

Semaglutide (Ozempic) was tied to a reduced risk of Alzheimer's disease diagnoses in people with type 2 diabetes, ...

Semaglutide, found in Novo Nordisk's Ozempic, may reduce Alzheimer's risk in type 2 diabetes patients, per new research. FDA ...

Semaglutide, the active ingredient found in Ozempic and Wegovy, may reduce the risk of Alzheimer’s disease, a new study published Thursday morning finds.

A new study is adding to evidence that GLP-1 drugs such as Novo Nordisk's semaglutide and Eli Lilly's tirzepatide could also ...

As obesity rates in the United States soar, insurance companies, including Medicaid and Medicare, are facing financial headwinds to pay for prescription drugs for weight loss. Semaglutide, the generic ...